• Alzheimer's research began with Alois Alzheimer's 1906 brain examination and the discovery of amyloid-beta plaques.
• The amyloid cascade hypothesis became the field's central model: plaques accumulate, plaques damage the brain, and plaque removal should stop Alzheimer's.
• That model drove more than a century of work, yet amyloid removal repeatedly failed to deliver a cure.

The Aβ*56 breakthrough

• In 2006, Sylvain Lesné at the University of Minnesota published the Nature paper that made Aβ*56 a candidate toxic culprit.
• Aβ*56 was a soluble oligomer, not a hard plaque, and the mouse work tied it to memory loss before plaque formation.
• The paper became field-shaping, drew thousands of citations, helped direct grant money, and sent labs and drug companies after amyloid oligomers.
• The goal was prevention: stop Aβ*56 early and stop Alzheimer's before the disease fully starts.

The image-manipulation scandal

• In 2022, Charles Piller's Science investigation, aided by Matthew Schrag's forensic image work, found Western blot problems in Lesné-linked work.
• The suspect images involved duplicated bands, inconsistent backgrounds, splicing, and other signs that protein evidence had been digitally altered.
• The image problems mattered because the images were the visual proof for Aβ*56 and its supposed link to memory loss.
• The scandal widened beyond the 2006 paper, with later concerns across additional Lesné papers and a University of Minnesota inquiry.
• Lesné remained in his role for years after exposure, deepening the sense that accountability was slow.

The human and financial cost

• Billions of dollars, thousands of research hours, young careers, and patient hopes moved toward amyloid oligomer work built on unstable evidence.
• Patients entered trials with invasive procedures, side effects, and hope for drugs linked to a story that could not bear the weight placed on it.
• Other disease mechanisms lost oxygen because funding and prestige kept flowing into amyloid-centered work.
• The scandal damages trust in peer review, top journals, academic oversight, and pharmaceutical incentives.

Anti-amyloid drugs after the scandal

• Lecanemab costs about $26,500 per year and removes amyloid, but it also carries ARIA risk, including brain swelling and bleeding.
• Clearing plaques does not equal restored memory; patients can still decline while amyloid burden falls.
• Amyloid is made by neurons, so removing it does not remove the reason the brain keeps making it.
• Aducanumab reached FDA approval amid controversy, advisory-committee resignations, weak clinical confidence, and later market withdrawal.

Why amyloid may be the wrong target

• Amyloid burden does not map cleanly onto cognitive decline; some people die with heavy amyloid and intact cognition.
• A 2008 amyloid-imaging study found amyloid deposition in cognitively normal older adults without worse cognitive function.
• Amyloid-beta also has antimicrobial activity, with mouse, worm, and cell work showing protection against microbial infection.
• This changes the core question from amyloid removal to why the brain mounts an amyloid defense and fails to clear it after danger passes.

The metabolic and infection model

• Alzheimer's fits a metabolic-disease model in which impaired brain glucose use leaves neurons under-fueled.
• The type 3 diabetes idea links Alzheimer's with brain insulin resistance and defective energy handling.
• Ketones offer an alternate fuel route when glucose handling is impaired, which is why low-carb, ketogenic, and carnivore approaches matter here.
• Chronic triggers such as herpes viruses, periodontal bacteria, gut pathogens, inflammation, and metabolic dysfunction can drive amyloid as a defense response.
• Brain-health prevention should center on metabolic health, infection control, vascular health, microvascular function, inflammation reduction, and insulin sensitivity.

Lessons from the scandal

• Follow the money when drug markets depend on one hypothesis staying alive.
• Question authority when prestigious journals miss manipulated work for sixteen years.
• Use joined-up thinking when plaques, symptoms, drug results, and healthy amyloid-positive brains do not fit the official story.
• Prevention beats late-stage plaque removal: nutrition, metabolic optimization, sleep, movement, and root-cause work come before expensive infusions.
• The brain evolved to run on real fuel and integrated physiology, not recurring IV antibody cycles that can injure the brain.

References

• [00:00] An English translation of Alzheimer's 1907 paper, "Über eine eigenartige Erkankung der Hirnrinde" — https://doi.org/10.1002/ca.980080612
• [00:01] Alzheimer's Disease: The Amyloid Cascade Hypothesis — https://doi.org/10.1126/science.1566067
• [00:01] A specific amyloid-β protein assembly in the brain impairs memory — https://doi.org/10.1038/nature04533
• [00:04] Blots on a field? — https://www.science.org/content/article/potential-fabrication-research-images-threatens-key-theory-alzheimers-disease
• [00:07] Lecanemab in Early Alzheimer's Disease — https://doi.org/10.1056/NEJMoa2212948
• [00:07] LEQEMBI Prescribing Information — https://www.leqembi.com/prescribinginformation
• [00:08] Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease — https://doi.org/10.14283/jpad.2022.30
• [00:08] Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019 — https://doi.org/10.1002/alz.12213
• [00:08] Three FDA advisory panel members resign over approval of Alzheimer's drug — https://doi.org/10.1136/bmj.n1503
• [00:08] Biogen to Realign Resources for Alzheimer's Disease Franchise — https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
• [00:08] Frequent Amyloid Deposition Without Significant Cognitive Impairment Among the Elderly — https://doi.org/10.1001/archneur.65.11.1509
• [00:09] The Alzheimer's Disease-Associated Amyloid β-Protein Is an Antimicrobial Peptide — https://doi.org/10.1371/journal.pone.0009505
• [00:10] Amyloid-β peptide protects against microbial infection in mouse and worm models of Alzheimer's disease — https://doi.org/10.1126/scitranslmed.aaf1059
• [00:11] Alzheimer's Disease is Type 3 Diabetes—Evidence Reviewed — https://doi.org/10.1177/193229680800200619
• [00:11] Randomized crossover trial of a modified ketogenic diet in Alzheimer's disease — https://doi.org/10.1186/s13195-021-00783-x
• [00:11] Alzheimer's Disease-Associated β-Amyloid Is Rapidly Seeded by Herpesviridae to Protect against Brain Infection — https://doi.org/10.1016/j.neuron.2018.06.030
• [00:11] Porphyromonas gingivalis in Alzheimer's disease brains: Evidence for disease causation and treatment with small-molecule inhibitors — https://doi.org/10.1126/sciadv.aau3333